XPO5 and hepatocellular carcinoma: Mechanistically, Pin1 inhibition by API-1 can upregulate miRNA biogenesis via retaining active XPO5 conformation, and suppress HCC development, indicating API-1 as a novel drug candidate for HCC therapy [34].